Albany, NY -- (ReleaseWire) -- 07/14/2014 -- According to a new market report published by Transparency Market Research "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011 - 2018," the global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is expected to reach USD 98.4 billion in 2018, growing at a CAGR of 9.9% from 2011 to 2018. In the overall global market, North America accounted for the highest share worth USD 19.9 billion in 2011 followed by Europe. However, with the continuous population and economic growth of the Asia-Pacific region, especially India and China, it is expected to witness the highest growth rate in the next six years.
Browse the full report athttp://www.transparencymarketresearch.com/diabetes-devices-market.html
Today, diabetes is one of the major areas of concern worldwide. The rising number of patients is due to the ever increasing population around the globe mainly in the Asia Pacific region. Currently, over 370 million people suffer from diabetes across the globe, which is expected to exceed 550 million by 2030. As of now, the age bracket of 40-59 years is the most affected diabetes population followed by the age group of 60-79 years. However, the age group of 60-79 years is expected to account for the highest number of diabetes patients by 2030.
The global diabetes therapeutics devices and drugs market is expected to reach USD 72.4 billion by 2018, growing at a CAGR of 10.4% from 2011 to 2018, whereas the global diagnosis and monitoring devices market is expected to reach USD 26.0 billion by 2018, growing at a CAGR of 7.8% for the same period. Major products in this market consist of glucose monitors, test strips, lancets, continuous blood glucose meters, software programs for diabetes monitoring, artificial pancreas, syringes, insulin, insulin pumps and other insulin delivery devices and anti-diabetic drugs. Of these, insulin devices, blood glucose monitoring devices, lancets and oral hypoglycemic agents are the most revenue generating products.
The rapidly growing diabetic population, sedentary lifestyle, rise in cases of obesity and inappropriate food habit are the major factors driving the growth of the global diabetes devices and drugs market. However, lack of awareness about diabetes diagnosis and treatment and adverse side effects of diabetes drugs are some of the factors acting as a restraint for this market. There are large numbers of diabetes patients left undiagnosed every year and this population is expected to grow further with rapid increase in population, in the coming future. This untapped market is likely to serve as an opportunity for the market players in the diabetes devices and drugs market.
Request Sample Report From here :
Some of the major players in the diabetes devices and drugs market are Novo Nordisk, Sanofi, Roche, LifeScan, Takeda, Medtronic, Ell Lilly, Abbott Laboratories and Bayer Healthcare, among others. Novo Nordisk accounted for the largest share, i.e., 27.4% in 2011 in the global diabetes therapeutics devices and drugs market followed by Sanofi accounting for 19.2%. However, F. Hoffmann-La Roche accounted for the highest share in the global diabetes diagnosis and monitoring devices market at 21.2% closely followed by LifeScan.
This research is specially designed to estimate and analyze the demand and performance of the diabetes devices and drugs products in a global scenario. The research provides in-depth analysis of diabetes devices and drugs product manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global diabetes devices and drugs market and provide in-depth analysis, historical data and statistically refined forecast for the segments covered.
The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the global diabetes devices and drugs market as below:
- Short Acting
- Long Acting
- Human Insulin
- Modern Insulin
- Animal Insulin
By Purchase Type
- Inhaled Insulin
- Insulin Pumps
Oral Hypoglycemic Agents
- KATP Blocker
- Alpha-Glucosidase Inhibitor
- Thiazolinediones/ Glitazones
- IncretinMimetics/ GLP-1 Analogs
- DPP-4 Inhibitors
- Amylin Mimetic
- SGLT2 Inhibitors
In addition the report provides a cross-sectional analysis of all the above segments with respect to the following five geographical markets:
- North America
- Middle East and Africa
- Latin America